Results 21 to 30 of about 197,154 (267)
Immune checkpoint inhibitor myocarditis: a systematic case study
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors.
E. A. Kushnareva, O. M. Moiseeva
doaj +1 more source
Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab [PDF]
Checkpoint inhibitor therapies are members of a new, groundbreaking class of drugs that reinvigorate the immune system to directly attack tumors.
Amulya Balagani +2 more
doaj +1 more source
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we used ...
Timothy J. Purwin +4 more
doaj +1 more source
Immune checkpoint inhibitor‐induced diabetes mellitus is a rare immune‐related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes.
Noriko Fujiwara +7 more
doaj +1 more source
Immune checkpoint inhibitors in malignancy [PDF]
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire +2 more sources
This case report presents a patient with metastatic malignant melanoma who was treated with immunotherapy with the PD-1 checkpoint inhibitor pembrolizumab and developed a rare neurological immune-related adverse event (irAE) limbic encephalitis.
Rozala Arko, Nina Boc, Marko Boc
doaj +1 more source
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam +6 more
doaj +1 more source
Immune checkpoint inhibitors [PDF]
Hui details the cell biology underlying the action of immune checkpoint inhibitors.
openaire +4 more sources
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian +5 more
doaj +1 more source
Immune checkpoint inhibitors have significantly improved the prognosis in patients with non-small cell lung cancer, compared with cytotoxic agents.
Minehiko Inomata +14 more
doaj +1 more source

